Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.46 |
| ▸ | HTT | P42858 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19104787 | 0.85 | TP53 (0.46) | KDM4ESMN1; SMN2HTTLMNAMAPT | |
| SCHEMBL17450497 | 0.83 | MAPT (0.50) | CYP11B1CYP11B2KDM4ESMN1; SMN2HTT | |
| SCHEMBL17446214 | 0.80 | CYP19A1 (0.46) | KDM4ESMN1; SMN2HTTLMNAMAPT | |
| SCHEMBL17450527 | 0.79 | ALDH1A1 (0.44) | KDM4ESMN1; SMN2HTTLMNAMAPT | |
| SCHEMBL17450526 | 0.76 | P2RX4 (0.47) | KDM4ELMNAALDH1A1GAAKMT2A | |
| SCHEMBL17446097 | 0.76 | LMNA (0.48) | KDM4ESMN1; SMN2HTTLMNAMAPT | |
| SCHEMBL17445991 | 0.73 | ALDH1A1 (0.48) | CYP11B1CYP11B2KDM4ESMN1; SMN2HTT | |
| SCHEMBL21943933 | 0.72 | TP53 (0.44) | KDM4ESMN1; SMN2HTTLMNAMAPT | |
| SCHEMBL19117075 | 0.72 | NPC1 (0.42) | CYP11B1CYP11B2KDM4ESMN1; SMN2MAPT | |
| SCHEMBL19104754 | 0.71 | KMT2A (0.46) | KDM4ESMN1; SMN2HTTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | OHIO UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | OHIO UNIVERSITY (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2016010611-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016010609-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | FABP1, LIPC, SLC10A1 | CYP11B1 105/4885CYP11B2 119/4885KDM4E 3973/4885 |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | CYP11B1 78/4885CYP11B2 106/4885KDM4E 4334/4885 |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | FABP1, LIPC, SLC10A1 | CYP11B1 105/4885CYP11B2 119/4885KDM4E 3973/4885 |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | CYP11B1 80/4885CYP11B2 109/4885KDM4E 4327/4885 |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | FGFR1, TYRO3, STAT6 | CYP11B1 80/4885CYP11B2 104/4885KDM4E 4351/4885 |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | FGFR1, TYRO3, STAT6 | CYP11B1 80/4885CYP11B2 104/4885KDM4E 4351/4885 |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | GSK3B, GSK3A, GSKIP | CYP11B1 929/4885CYP11B2 1005/4885KDM4E 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.